Novartis has had nothing but upbeat things to say about their hot new migraine drug Aimovig and the reengineered collaboration pact with Amgen back in 2017 that gave them half of the lucrative US market.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription